Companies Paragon 28
Paragon 28 (FNA): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Paragon 28 no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers7th pct.Of 20 peer CEOs
CEO pay, last three years
- $4,650,087FY2021
- $5,214,743FY2022
- $3,232,420FY2023
CEO total pay was $3,232,420 in fiscal 2023, down from $5,214,743 in fiscal 2022.
FY2023: salary $700,769 · bonus $0 · stock awards $1,832,495 · option awards $0
Executives and directors
Albert DaCosta · CEOJason Edie · CTOAndrew Hill · EVPRobert McCormack · General CounselMatthew Jarboe · CCOStephen Deitsch · CFOAlf Grunwald · Independent DirectorB. Kristine Johnson · Independent DirectorKristina Wright · DirectorMeghan Scanlon · Independent DirectorQuentin Blackford · Independent DirectorStephen Oesterle · Independent DirectorThomas Schnettler · Lead Independent Director
Frequently asked questions
Who was the highest-paid executive at Paragon 28 in fiscal 2023?
As disclosed, Albert DaCosta (Chairman, President and Chief Executive Officer) was the highest-paid executive at Paragon 28 in fiscal 2023, with total compensation of $3,232,420.
How does Paragon 28's chief executive pay compare to its disclosed peer group?
As disclosed, Albert DaCosta's total compensation ranked at the 7th percentile of Paragon 28's disclosed peer group.
How much does Paragon 28 spend in total on board compensation for fiscal 2023?
As disclosed, Paragon 28 reported total board compensation of $1,528,111 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Albert DaCosta | $700,769 | $0 | $1,832,495 | $0 | $667,400 | $0 | $31,757 | $3,232,420 |
| Chairman, President and Chief Executive Officer | ||||||||
| Matthew Jarboe | 538,531 | 0 | 635,003 | 0 | 329,940 | 0 | 31,445 | 1,534,918 |
| Chief Commercial Officer | ||||||||
| Stephen Deitsch | 478,385 | 0 | 698,995 | 0 | 296,335 | 0 | 31,757 | 1,505,471 |
| Chief Financial Officer | ||||||||
| Robert McCormack | 148,923 | 0 | 924,994 | 0 | 78,584 | 0 | 8,764 | 1,161,265 |
| General Counsel and Corporate Secretary | ||||||||
| Jason Edie | 221,162 | 82,156 | 463,001 | 0 | 0 | 0 | 388,949 | 1,155,268 |
| Former Chief Technology Officer | ||||||||
| Andrew Hill | 57,692 | 0 | 999,992 | 0 | 0 | 0 | 3,759 | 1,061,444 |
| Executive Vice President of Research and Development | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Albert DaCosta | $3,232,420 | $5,214,743 | $4,650,087 | ↓ −1,982,323 |
| Matthew Jarboe | 1,534,918 | 2,255,390 | 2,097,440 | ↓ −720,472 |
| Stephen Deitsch | 1,505,471 | 2,224,321 | 1,895,603 | ↓ −718,850 |
| Robert McCormack | 1,161,265 | — | — | — |
| Jason Edie | 1,155,268 | 2,457,580 | — | ↓ −1,302,312 |
| Andrew Hill | 1,061,444 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Historically, our executive compensation program has been designed to motivate, reward, attract and retain high caliber management deemed critical to our success. The program seeks to align executive compensation with our short-term and long-term objectives, financial performance and stockholder priorities.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Stephen Deitsch | RSU | 2023-02-28 | — | — | 39,050 | — | $698,995 |
| Andrew Hill | RSU | 2023-10-23 | — | — | 85,910 | — | 999,992 |
| Matthew Jarboe | RSU | 2023-02-28 | — | — | 35,475 | — | 635,003 |
| Albert DaCosta | RSU | 2023-02-28 | — | — | 102,374 | — | 1,832,495 |
| Robert McCormack | PSU | 2023-08-14 | — | — | 54,961 | — | 924,994 |
| Jason Edie | PSU | 2023-02-28 | — | — | 25,866 | — | 463,001 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Stephen Deitsch | $698,995 | $0 | $0 | 0.0% |
| Andrew Hill | 999,992 | 0 | 0 | 0.0% |
| Matthew Jarboe | 635,003 | 0 | 0 | 0.0% |
| Albert DaCosta | 1,832,495 | 0 | 0 | 0.0% |
| Robert McCormack | 0 | 924,994 | 0 | 100.0% |
| Jason Edie | 0 | 463,001 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jason Edie | RSU | 6,467 | — | $80,385 |
| Matthew Jarboe | RSU | 35,475 | — | 440,954 |
| Stephen Deitsch | RSU | 39,050 | — | 485,392 |
| Jason Edie | Option | 51,230 | 17.72 | — |
| Matthew Jarboe | RSU | 53,601 | — | 666,260 |
| Robert McCormack | RSU | 54,961 | — | 683,165 |
| Stephen Deitsch | RSU | 59,004 | — | 733,420 |
| Stephen Deitsch | Option | 71,131 | 16 | — |
| Matthew Jarboe | Option | 71,131 | 16 | — |
| Andrew Hill | RSU | 85,910 | — | 1,067,861 |
| Albert DaCosta | RSU | 102,374 | — | 1,272,509 |
| Stephen Deitsch | Option | 125,000 | 6 | — |
| Albert DaCosta | RSU | 154,684 | — | 1,922,722 |
| Albert DaCosta | Option | 206,609 | 16 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Thomas SchnettlerIndependent · Lead Independent Director · Audit | $95,000 | $150,000 | $0 | — | $0 | $245,000 |
| Kristina WrightEmployee director · Audit (Chair) | 70,000 | 150,000 | 0 | — | 0 | 220,000 |
| Quentin BlackfordIndependent · Audit · Compensation (Chair) | 70,000 | 150,000 | 0 | — | 0 | 220,000 |
| B. Kristine JohnsonIndependent · Compensation · Nominating and Corporate Governance (Chair) | 62,500 | 150,000 | 0 | — | 0 | 212,500 |
| Meghan ScanlonIndependent · Compensation · Nominating and Corporate Governance · Quality, Technology and Regulatory | 60,611 | 150,000 | 0 | — | 0 | 210,611 |
| Alf GrunwaldIndependent · Audit · Quality, Technology and Regulatory | 60,000 | 150,000 | 0 | — | 0 | 210,000 |
| Stephen OesterleIndependent · Nominating and Corporate Governance · Quality, Technology and Regulatory (Chair) | 60,000 | 150,000 | 0 | — | 0 | 210,000 |
| Albert DaCostaEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $150,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 4x annual retainer |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $478,111 |
| Equity awards (grant-date value) | $1,050,000 |
| All other compensation | $0 |
| Total cost of the board | $1,528,111 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Paragon 28 as a peer
Companies that benchmark against FNA
7 companies name FNA as a compensation peer
- ARTIVION, INC.AORTFY2025
- Axogen, Inc.AXGNFY2025
- Organogenesis Holdings Inc.ORGOFY2025
- Outset Medical, Inc.OMFY2025
- PROCEPT BioRobotics CorpPRCTFY2025
- SI-BONE, Inc.SIBNFY2025
- ZimVie Inc.ZIMVFY2024
Each company listed discloses FNA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named FNA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
NARI Inari Medical SeaSpine HoldingsAXGN AxoGenIRTC iRhythm TechnologiesCYRX CryoportATEC Alphatec HoldingsATRC AtriCureAXNX AxonicsGKOS Glaukos HeskaLMAT LeMaitre VascularNVRO NevroOFIX Orthofix Medical OrthoPediatics ShockwaveSIBN SI-BONESILK Silk Road MedicalTNDM Tandem Diabetes CareTMCI Treace Medical ConceptsVCEL Vericel
Peer reciprocity
The companies Paragon 28 names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Silk Road Medical | 2023 | Chas McKhann | $105,871 | $13,123,059 | $0 | $93,275 | $13,423,834 |
| 2 | Glaukos | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 3 | Nevro | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 4 | Vericel | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 5 | iRhythm Technologies | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 6 | Alphatec Holdings | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 7 | AtriCure | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 8 | AxoGen | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 9 | SI-Bone | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 10 | Orthofix Medical | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 11 | Tandem Diabetes Care | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 12 | Treace Medical Concepts | 2025 | John Treace | 755,353 | 4,635,000 | 0 | 0 | 5,405,190 |
| 13 | Inari Medical | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| 14 | LeMaitre Vascular | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 15 | Paragon 28 | 2023 | Albert DaCosta | 700,769 | 1,832,495 | 0 | 667,400 | 3,232,420 |
| 16 | Cryoport | 2025 | Jerrell Shelton | 967,845 | 192,300 | 306,869 | 908,510 | 2,375,524 |
| — | Axonics | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Paragon 28 | 94% | RSU 100 | not disclosed | Compensia, Inc. |
| Alphatec Holdings | 157% | PSU 50 · RSU 50 | No | Compensia |
| AtriCure | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| AxoGen | 116.79% | PSU 50 · RSU 50 | No | Aon |
| Axonics | not disclosed | not disclosed | not disclosed | not disclosed |
| Cryoport | 92.2% | not disclosed | not disclosed | Frederic W. Cook & Co., Inc. |
| Glaukos | not disclosed | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Inari Medical | 118% | RSU 75 · Option 25 | not disclosed | FW Cook |
| iRhythm Technologies | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| LeMaitre Vascular | not disclosed | Option 50 · RSU 25 · PSU 25 | No | not disclosed |
| Nevro | 53.7% | not disclosed | No | Aon |
| Orthofix Medical | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| SI-Bone | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| Silk Road Medical | not disclosed | PSU 50 · RSU 50 | Yes — Total Stockholder Return (TSR) relative to peer group | Compensia, Inc. |
| Tandem Diabetes Care | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| Treace Medical Concepts | not disclosed | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Vericel | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| MVM Partners, LLC | Greater-than-10% holder | 2025-01-23 | D | 20,136 | $12 | $234,101 | Common, indirect | Form 4 ↗ |
| MVM Partners, LLC | Greater-than-10% holder | 2025-01-24 | D | 25,026 | 12 | 290,176 | Common, indirect | Form 4 ↗ |
| MVM Partners, LLC | Greater-than-10% holder | 2025-01-27 | D | 27,142 | 12 | 315,425 | Common, indirect | Form 4 ↗ |
| MVM Partners, LLC | Greater-than-10% holder | 2025-01-28 | D | 84,323 | 12 | 1,006,648 | Common, indirect | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-02-28 | D | 4,136 | 13 | 53,933 | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-02-28 | D | 11,341 | 13 | 147,887 | Common | Form 4 ↗ |
| MVM Partners, LLC | Greater-than-10% holder | 2025-03-04 | D | 619,747 | 13 | 8,053,116 | Common, indirect | Form 4 ↗ |
| MVM Partners, LLC | Greater-than-10% holder | 2025-03-05 | D | 590,224 | 13 | 7,684,362 | Common, indirect | Form 4 ↗ |
| MVM Partners, LLC | Greater-than-10% holder | 2025-03-06 | D | 164,664 | 13 | 2,142,592 | Common, indirect | Form 4 ↗ |
| Robert McCormack | See Remarks | 2025-03-10 | D | 8,165 | 13 | 106,227 | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-03-10 | D | 18,258 | 13 | 237,537 | Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-03-10 | D | 10,732 | 13 | 139,623 | Common | Form 4 ↗ |
| MVM Partners, LLC | Greater-than-10% holder | 2025-03-13 | D | 1,044,295 | 13 | 13,618,129 | Common, indirect | Form 4 ↗ |
| Albert DaCosta | Director | 2025-03-14 | A | 2,061,702 | 0 | 0 | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-03-14 | D | 2,061,702 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Hill | EVP of Research & Development | 2025-03-20 | A | 49,884 | 0 | 0 | Common | Form 4 ↗ |
| Robert McCormack | See Remarks | 2025-03-20 | A | 90,867 | 0 | 0 | Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-03-20 | A | 117,344 | 0 | 0 | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-03-20 | A | 337,682 | 0 | 0 | Common | Form 4 ↗ |
| Chadi Chahine | See Remarks | 2025-03-20 | A | 145,817 | 0 | 0 | Common | Form 4 ↗ |
| Thomas Schnettler | Director | 2025-04-21 | D | 45,035 | — | — | Common | Form 4 ↗ |
| David M. Demski | Director | 2025-04-21 | D | 74,307 | — | — | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 233,694 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 2,061,702 | — | — | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 3,277,408 | — | — | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 1,314,614 | — | — | Common | Form 4 ↗ |
| Chadi Chahine | See Remarks | 2025-04-21 | D | 174,769 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Quentin Blackford | Director | 2025-04-21 | D | 50,554 | — | — | Common | Form 4 ↗ |
| Andrew Hill | EVP of Research & Development | 2025-04-21 | D | 126,397 | — | — | Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 155,210 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 175,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 575,320 | — | — | Common | Form 4 ↗ |
| B. Kristine Johnson | Director | 2025-04-21 | D | 47,347 | — | — | Common | Form 4 ↗ |
| Stephen Oesterle | Director | 2025-04-21 | D | 250,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen Oesterle | Director | 2025-04-21 | D | 40,216 | — | — | Common | Form 4 ↗ |
| Meghan Scanlon | Director | 2025-04-21 | D | 42,113 | — | — | Common | Form 4 ↗ |
| Robert McCormack | See Remarks | 2025-04-21 | D | 20,014 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Robert McCormack | See Remarks | 2025-04-21 | D | 203,134 | — | — | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 450,778 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chadi Chahine | See Remarks | 2025-04-21 | D | 520,657 | — | — | Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 27,588 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Hill | EVP of Research & Development | 2025-04-21 | D | 10,818 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kristina Wright | Director | 2025-04-21 | D | 32,118 | — | — | Common | Form 4 ↗ |
| Alf Grunwald | Director | 2025-04-21 | D | 51,935 | — | — | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 100,000 | — | — | Common | Form 4 ↗ |
| Albert DaCosta | Director | 2025-04-21 | D | 5,000,000 | — | — | Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Jarboe | Chief Commercial Officer | 2025-04-21 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (98 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Albert DaCosta. DEF 14A, filed 2024-04-05. Section “2023 Summary Compensation Table” · page 51. As printed: 3,232,420. View filing ↗
- Section 01, Matthew Jarboe. DEF 14A, filed 2024-04-05. Section “2023 Summary Compensation Table” · page 51. As printed: 1,534,918. View filing ↗
- Section 01, Stephen Deitsch. DEF 14A, filed 2024-04-05. Section “2023 Summary Compensation Table” · page 51. As printed: 1,505,471. View filing ↗
- Section 01, Robert McCormack. DEF 14A, filed 2024-04-05. Section “2023 Summary Compensation Table” · page 51. As printed: 1,161,265. View filing ↗
- Section 01, Jason Edie. DEF 14A, filed 2024-04-05. Section “2023 Summary Compensation Table” · page 51. As printed: 1,155,268. View filing ↗
- Section 01, Andrew Hill. DEF 14A, filed 2024-04-05. Section “2023 Summary Compensation Table” · page 51. As printed: 1,061,444. View filing ↗
- Section 03, Stephen Deitsch RSU. DEF 14A, filed 2024-04-05. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Hill RSU. DEF 14A, filed 2024-04-05. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Jarboe RSU. DEF 14A, filed 2024-04-05. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Albert DaCosta RSU. DEF 14A, filed 2024-04-05. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Robert McCormack PSU. DEF 14A, filed 2024-04-05. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Jason Edie PSU. DEF 14A, filed 2024-04-05. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 08, Thomas Schnettler. DEF 14A, filed 2024-04-05. Section “Director Compensation”. As printed: 245,000. View filing ↗
- Section 08, Kristina Wright. DEF 14A, filed 2024-04-05. Section “Director Compensation”. As printed: 220,000. View filing ↗
- Section 08, Quentin Blackford. DEF 14A, filed 2024-04-05. Section “Director Compensation”. As printed: 220,000. View filing ↗
- Section 08, B. Kristine Johnson. DEF 14A, filed 2024-04-05. Section “Director Compensation”. As printed: 212,500. View filing ↗
- Section 08, Meghan Scanlon. DEF 14A, filed 2024-04-05. Section “Director Compensation”. As printed: 210,611. View filing ↗
- Section 08, Alf Grunwald. DEF 14A, filed 2024-04-05. Section “Director Compensation”. As printed: 210,000. View filing ↗
- Section 08, Stephen Oesterle. DEF 14A, filed 2024-04-05. Section “Director Compensation”. As printed: 210,000. View filing ↗
- Section 08, Albert DaCosta. DEF 14A, filed 2024-04-05. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, MVM Partners, LLC 2025-01-23. Form 4, filed 2025-01-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MVM Partners, LLC 2025-01-24. Form 4, filed 2025-01-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MVM Partners, LLC 2025-01-27. Form 4, filed 2025-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MVM Partners, LLC 2025-01-28. Form 4, filed 2025-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-02-28. Form 4, filed 2025-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MVM Partners, LLC 2025-03-04. Form 4, filed 2025-03-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MVM Partners, LLC 2025-03-05. Form 4, filed 2025-03-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MVM Partners, LLC 2025-03-06. Form 4, filed 2025-03-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert McCormack 2025-03-10. Form 4, filed 2025-03-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-03-10. Form 4, filed 2025-03-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-03-10. Form 4, filed 2025-03-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, MVM Partners, LLC 2025-03-13. Form 4, filed 2025-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-03-14. Form 4, filed 2025-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-03-14. Form 4, filed 2025-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hill 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert McCormack 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chadi Chahine 2025-03-20. Form 4, filed 2025-03-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Schnettler 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David M. Demski 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chadi Chahine 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Quentin Blackford 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hill 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, B. Kristine Johnson 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Oesterle 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Oesterle 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meghan Scanlon 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert McCormack 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert McCormack 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chadi Chahine 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Hill 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristina Wright 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alf Grunwald 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Albert DaCosta 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Jarboe 2025-04-21. Form 4, filed 2025-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 478,111 + equity 1,050,000 + all other 0 = 1,528,111, summed across the director compensation table rows.
- Silk Road Medical, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Silk Road Medical's own proxy. As printed: 13,423,834. View filing ↗
- Glaukos, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. View filing ↗
- Nevro, Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. View filing ↗
- Vericel, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. View filing ↗
- iRhythm Technologies, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Technologies's own proxy. As printed: 11,003,163. View filing ↗
- Alphatec Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings's own proxy. As printed: 10,260,507. View filing ↗
- AtriCure, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure's own proxy. As printed: 9,217,620. View filing ↗
- AxoGen, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in AxoGen's own proxy. As printed: 9,047,454. View filing ↗
- SI-Bone, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in SI-Bone's own proxy. As printed: 7,453,235. View filing ↗
- Orthofix Medical, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orthofix Medical's own proxy. As printed: 7,310,039. View filing ↗
- Tandem Diabetes Care, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care's own proxy. As printed: 6,858,503. View filing ↗
- Treace Medical Concepts, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Treace Medical Concepts's own proxy. As printed: 5,405,190. View filing ↗
- Inari Medical, Section 10b CEO total. DEF 14A, filed 2024-03-13. CEO total compensation as printed in Inari Medical's own proxy. As printed: 5,083,365. View filing ↗
- LeMaitre Vascular, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in LeMaitre Vascular's own proxy. As printed: 3,780,990. View filing ↗
- Paragon 28 (subject), Section 10b CEO total. DEF 14A, filed 2024-04-05. CEO total compensation as printed in Paragon 28's own proxy. As printed: 3,232,420. View filing ↗
- Cryoport, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cryoport's own proxy. As printed: 2,375,524. View filing ↗
- Section 10a, AxoGen reciprocity. DEF 14A. AxoGen names Paragon 28 in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, SI-BONE reciprocity. DEF 14A. SI-BONE names Paragon 28 in its own disclosed peer group (read from its most recent proxy). View filing ↗